GlycoMark-logo.png

An FDA-cleared and CE-Marked blood test specific to detecting recent hyperglycemia, glycemic variability, and pancreatic beta-cell mass

 
Male Scientist

About GlycoMark®

  • An FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring in the fasting state, postprandial, or both).

  • Reveals recent trends toward or away from A1C goals, suggesting improving or worsening control.

  • Is Independently associated with increased rates of diabetes complications.

  • When used with A1C, provides a more complete assessment of glycemic control to identify patients that may benefit from closer diabetes management.

  • New studies show GlycoMark is a biomarker of functional pancreatic beta-cell mass in patients at risk for diabetes. 

 

For More Information

Visit www.glycomark.com

The GlycoMark test is FDA cleared for professional use to provide quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The GlycoMark test is intended for intermediate-term monitoring of glycemic control in patients with diabetes.